X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1277) 1277
valine - analogs & derivatives (1111) 1111
male (876) 876
female (801) 801
valine - therapeutic use (687) 687
valsartan (627) 627
middle aged (599) 599
adult (458) 458
valine - adverse effects (455) 455
aged (431) 431
tetrazoles - therapeutic use (406) 406
valine - administration & dosage (353) 353
hypertension - drug therapy (344) 344
acyclovir - analogs & derivatives (339) 339
treatment outcome (297) 297
tetrazoles - adverse effects (262) 262
animals (258) 258
antihypertensive agents - therapeutic use (250) 250
pharmacology & pharmacy (244) 244
acyclovir - therapeutic use (236) 236
valine (226) 226
antiviral agents - therapeutic use (225) 225
hypertension (225) 225
double-blind method (217) 217
drug therapy, combination (209) 209
valine - pharmacology (208) 208
tetrazoles - administration & dosage (203) 203
blood pressure - drug effects (201) 201
antihypertensive agents - adverse effects (185) 185
angiotensin ii type 1 receptor blockers - therapeutic use (171) 171
valacyclovir (167) 167
acyclovir - adverse effects (155) 155
antiviral agents - adverse effects (146) 146
antihypertensive agents - administration & dosage (142) 142
risk factors (136) 136
dose-response relationship, drug (134) 134
drug therapy (134) 134
peripheral vascular disease (129) 129
tetrazoles - pharmacology (128) 128
medicine, general & internal (126) 126
rats (124) 124
time factors (123) 123
adolescent (119) 119
hypertension - physiopathology (118) 118
amino acids (117) 117
double-blind (116) 116
acyclovir - administration & dosage (115) 115
cardiac & cardiovascular systems (112) 112
prevention (112) 112
aged, 80 and over (110) 110
acyclovir (108) 108
leucine (108) 108
valine - genetics (108) 108
antiviral agents - administration & dosage (106) 106
research (105) 105
analysis (103) 103
angiotensin-converting enzyme inhibitors - therapeutic use (101) 101
metabolism (101) 101
mortality (101) 101
therapy (100) 100
prospective studies (99) 99
health aspects (96) 96
isoleucine (94) 94
angiotensin ii type 1 receptor blockers - adverse effects (93) 93
blood pressure (92) 92
blood-pressure (90) 90
administration, oral (88) 88
valine - pharmacokinetics (87) 87
follow-up studies (86) 86
risk (86) 86
young adult (86) 86
randomized controlled trials as topic (85) 85
care and treatment (83) 83
efficacy (83) 83
amlodipine (82) 82
heart failure - drug therapy (82) 82
neurosciences (82) 82
angiotensin receptor antagonists (81) 81
internal medicine (81) 81
angiotensin (79) 79
genotype (79) 79
disease (78) 78
oncology (75) 75
drug combinations (72) 72
heart failure (71) 71
medicine & public health (70) 70
mice (70) 70
antihypertensive agents - pharmacology (69) 69
losartan (69) 69
psychiatry (69) 69
amlodipine - therapeutic use (68) 68
medicine (68) 68
hydrochlorothiazide - therapeutic use (67) 67
toxicology (66) 66
trial (66) 66
methionine - genetics (65) 65
proteins (65) 65
hydrochlorothiazide - administration & dosage (64) 64
herpes zoster - drug therapy (63) 63
management (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1488) 1488
German (30) 30
Spanish (14) 14
French (13) 13
Japanese (12) 12
Russian (11) 11
Chinese (7) 7
Italian (3) 3
Swedish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9932, pp. 1889 - 1898
... has been associated with improved blood pressure control,1–4 lower rates of adverse events, and improved drug adherence.3–6 Moreover, fixed-dose combinations make the assessment... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | MONOTHERAPY | METAANALYSIS | BETA-BLOCKERS | TOLERABILITY | Benzopyrans - adverse effects | Ethanolamines - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzopyrans - therapeutic use | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Valine - administration & dosage | Ethanolamines - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Tetrazoles - administration & dosage | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Nebivolol | Double-Blind Method | Drug Administration Schedule | Valine - analogs & derivatives | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Benzopyrans - administration & dosage | Ethanolamines - therapeutic use | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Drug Combinations | Hypertension | Usage | Patient outcomes | Dosage and administration | Drug therapy | Oxidative stress | Health Insurance Portability & Accountability Act 1996-US | Cardiovascular disease | Blood pressure | Drug dosages
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 370, Issue 9583, pp. 221 - 229
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2008, Volume 48, Issue 1, pp. 85 - 95
.... Coadministration of vildagliptin 100 mg with amlodipine 5 mg, valsartan 320 mg, or ramipril 5 mg had no clinically significant effect on the pharmacokinetics of these drugs. The 90... 
type 2 diabetes | vildagliptin | calcium channel blocker | Dipeptidyl peptidase IV inhibitor | angiotensin converting enzyme inhibitor | pharmacokinetics | angiotensin receptor blocker | Type 2 diabetes | Angiotensin converting enzyme inhibitor | Calcium channel blocker | Vildagliptin | Angiotensin receptor blocker | Pharmacokinetics | LAF237 | RISK | PHARMACODYNAMICS | BLOOD-PRESSURE | DIABETES-MELLITUS | BIOTRANSFORMATION | MEN | PHARMACOLOGY & PHARMACY | HYPERTENSION | TYPE-2 | STAGE RENAL-DISEASE | dipeptidyl peptidase IV inhibitor | Nausea - chemically induced | Tablets | Humans | Middle Aged | Half-Life | Pyrrolidines - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Nitriles - pharmacokinetics | Ramipril - administration & dosage | Drug Interactions | Tetrazoles - administration & dosage | Ramipril - analogs & derivatives | Adamantane - administration & dosage | Ramipril - adverse effects | Amlodipine - administration & dosage | Adamantane - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Administration, Oral | Pyrrolidines - pharmacokinetics | Amlodipine - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Valine - adverse effects | Nitriles - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Valsartan | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Pyrrolidines - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics | Valine - administration & dosage | Nitriles - administration & dosage | Amlodipine - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Headache - chemically induced | Adamantane - pharmacokinetics | Adamantane - adverse effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Ramipril - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Tetrazoles - adverse effects | Amlodipine | Dosage and administration | Enzyme inhibitors | Research
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2012, Volume 34, Issue 8, pp. 1735 - 1750
.... However, the effects of combination therapy may be diverse because of the different components... 
Internal Medicine | Medical Education | diabetes | fixed-dose combination | hypertension | noninferiority | Hypertension | Diabetes | Fixed-dose combination | Noninferiority | MANAGEMENT | ALBUMINURIA | HYDROCHLOROTHIAZIDE | AMLODIPINE | TELMISARTAN | THERAPY | HIGH-RISK | TOLERABILITY | RENAL OUTCOMES | PHARMACOLOGY & PHARMACY | VALSARTAN | Angiotensin II Type 1 Receptor Blockers - adverse effects | Prospective Studies | Calcium Channel Blockers - adverse effects | Valsartan | Benzazepines - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Valine - administration & dosage | Time Factors | Tetrazoles - administration & dosage | Lipids - blood | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Blood Pressure - drug effects | Uric Acid - blood | Hypertension - diagnosis | Amlodipine - administration & dosage | Diabetes Mellitus, Type 2 - complications | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Hydrochlorothiazide - adverse effects | Diuretics - administration & dosage | Albuminuria - etiology | Double-Blind Method | Valine - analogs & derivatives | Amlodipine - adverse effects | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Calcium Channel Blockers - administration & dosage | Taiwan | Hypertension - complications | Aged | Benzazepines - administration & dosage | Tetrazoles - adverse effects | Valine - adverse effects | Blood Glucose - metabolism | Diuretics - adverse effects | Drug Combinations | Type 2 diabetes | Medical research | Diabetics | Medical colleges | Care and treatment | Complications and side effects | Amlodipine | Diuretics | Medicine, Experimental | Benazepril | Dosage and administration | Drug therapy, Combination | Comparative analysis | Studies | Body mass index | Heart attacks | Disease | Mortality | Blood pressure | Kidney diseases | Regression analysis | Drug dosages
Journal Article
Neuro-Oncology, ISSN 1522-8517, 08/2016, Volume 18, Issue 8, pp. 1137 - 1145
Journal Article
Haematologica, ISSN 0390-6078, 12/2005, Volume 90, Issue 12, pp. 1672 - 1679
Division of Hematology & Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia. dr.ashley.ng@gmail.com... 
Cytomegalovirus | Ganciclovir | CMV DNAemia | CMV disease | Cyclophosphamide - administration & dosage | Acyclovir - therapeutic use | Follow-Up Studies | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Dexamethasone - adverse effects | Male | Cyclophosphamide - adverse effects | Diphtheria Toxin - adverse effects | Ganciclovir - therapeutic use | Vincristine - administration & dosage | Cytomegalovirus - physiology | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Antiviral Agents - therapeutic use | Rituximab | Viremia - drug therapy | Antimetabolites, Antineoplastic - therapeutic use | Cytomegalovirus Infections - drug therapy | Viremia - prevention & control | Antimetabolites, Antineoplastic - adverse effects | Fever - etiology | Hematologic Neoplasms - drug therapy | Vincristine - adverse effects | Viremia - epidemiology | Valine - therapeutic use | Viremia - etiology | Cohort Studies | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytomegalovirus Infections - epidemiology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - adverse effects | Interleukin-2 - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Antibodies, Monoclonal, Humanized | Cytomegalovirus Infections - prevention & control | Diphtheria Toxin - therapeutic use | Polymerase Chain Reaction | Cytomegalovirus Infections - etiology | Adult | Female | Retrospective Studies | Hematologic Neoplasms - complications | Virus Activation | Doxorubicin - administration & dosage | Cytomegalovirus - isolation & purification | Acyclovir - analogs & derivatives | Valine - analogs & derivatives | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Alemtuzumab | Vidarabine - therapeutic use | DNA, Viral - blood | Hematologic Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Peripheral Blood Stem Cell Transplantation | Doxorubicin - adverse effects | Antibodies, Neoplasm - adverse effects | ALEMTUZUMAB CAMPATH-1H | MULTIPLE-MYELOMA | RISK-FACTORS | IMMUNE RECONSTITUTION | PERIPHERAL-BLOOD | ganciclovir | POLYMERASE-CHAIN-REACTION | cytomegalovirus | CLINICAL UTILITY | AUTOLOGOUS BONE-MARROW | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | ANTI-CD52 MONOCLONAL-ANTIBODY
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 369, Issue 9579, pp. 2079 - 2087
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2008, Volume 52, Issue 3, pp. 501 - 506
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2008, Volume 7, Issue 11, pp. 993 - 1000
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 11/2010, Volume 5, Issue 11, pp. 1928 - 1938
Background and objectives: This open, prospective, randomized trial aimed to assess the effects of statins in chronic kidney disease patients on optimized antiproteinuric treatment with combined angiotensin-converting enzyme... 
MULTICENTER | METAANALYSIS | ALBUMINURIA | UROLOGY & NEPHROLOGY | OUTCOMES | DYSLIPIDEMIA | CHRONIC KIDNEY-DISEASE | STATINS | PROGRESSION | CHRONIC-RENAL-FAILURE | ATORVASTATIN | Blood Pressure | Kidney Diseases - physiopathology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Prospective Studies | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Benzazepines - adverse effects | Humans | Middle Aged | Male | Fatty Acids, Monounsaturated - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Fatty Acids, Monounsaturated - adverse effects | Lipids - blood | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Kidney Diseases - complications | Drug Therapy, Combination | Proteinuria - etiology | Glomerular Filtration Rate | Valine - analogs & derivatives | Kidney Diseases - drug therapy | Treatment Outcome | Chi-Square Distribution | Proteinuria - physiopathology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Proteinuria - drug therapy | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Indoles - therapeutic use | Italy | Renin-Angiotensin System - drug effects | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Chronic Disease | Original
Journal Article